Drug approved in Argentina for treatment of Chagas disease in children

Buenos Aires, Argentina – 13 April 2018
Argentina has approved the paediatric indication of a drug used for treatment of Chagas disease, benznidazole, which will now be available in 12.5 mg pills, the dose required to treat children under the age of 2. The indication was approved by the Argentinian National Administration for Drugs, Food, and Medical Technologies (ANMAT).

ISNTD 2018

25-26 June 2018 
London, UK
Ivan Scandale, Senior Project Manager, Discovery – presentation on the filarial research landscape
Eric StobbaertsInternational Development Director – presentation on access to Chagas treatments in Latin America

DNDi welcomes Astellas to the NTD Drug Discovery Booster

The Japanese pharmaceutical company Astellas Pharma Inc. is the eighth pharmaceutical company to join the Neglected Tropical Diseases Drug Discovery Booster, a global consortium launched in 2015 by DNDi to speed up the process and cut the cost of finding new treatments for leishmaniasis and Chagas disease.

DNDi, GlaxoSmithKline, and University of Dundee to identify drug candidates to treat leishmaniasis and Chagas disease

Geneva / Brentford / Dundee – 27 March 2018
The not-for-profit research and development organization Drugs for Neglected Diseases initiative (DNDi) will collaborate with GlaxoSmithKline (GSK), and the University of Dundee Drug Discovery Unit (DDU), in a bid to discover new pre-clinical drug candidates targeting two parasitic neglected tropical diseases (NTDs), leishmaniasis and Chagas disease.

Geneva Health Forum

7th Edition: Precision Global Health in the Digital Age

10-12 April 2018
Geneva, Switzerland
Bernard Pécoul, Executive Director – plenary talk on emerging infectious diseases crisis
Digas Ngolo, Investigator Coordinator, DNDi Africa – parallel session on ehealth

ISGlobal XIV Taller sobre la enfermedad de Chagas

8 March 2018
Barcelona, Spain
Sergio Sosa-Estani, Head of Chagas, DNDi Latin America – presentation about control programmes for congenital Chagas disease
Michel Lotrowska, Acting Regional Director, DNDi Latin America – participation in the annual meeting Chagas coalition

Le Quotidien du Médecin [16 January 2018]

“Après 40 ans sans avancée, les premiers pas d’un nouveau traitement de la maladie de Chagas chronique” – “After 40 years without advance, the first steps of a new treatment for chronic Chagas disease”

Click here to read the article

18th International Congress on Infectious Diseases

1-4 March 2018
Buenos Aires, Argentina
Sergio Sosa-Estani, Head of Chagas, DNDi Latin America – presentation on Chagas disease
Byron Arana, Head of Cutaneous Leishmaniasis, DNDi – parallel symposium on cutaneous leishmaniasis
Graciela Diap, Paediatric HIV/HCV, DNDi, and Francisco Viegas Neves da Silva, Regional Policy Advocacy Consultant, DNDi Latin America – parallel symposium on hepatitis C

Chagas Symposium IC-18

14-16 February 2018
London, UK
Sergio Sosa-Estani, Head of Chagas, DNDi Latin America – presentation on the progress on diagnostics and treatments for Chagas disease